Print this page    •   Back to Web version of article

Trugene OK'd by FDA

December 2001/January 2002

A test to gauge resistance to HIV drugs has been cleared for marketing by the Food and Drug Administration.

Trugene HIV-1 Genotyping Kit and OpenGeneDNA Sequencing System, developed by Visible Genetics Inc., was submitted to the FDA as an integrated system including chemistry, hardware, software and patient report necessary to generate test results. The report offers a health care provider information regarding antiretroviral drugs that are likely to be effective in the treatment of HIV infection.

The test allows physicians to personalize therapy for individual HIV patients, said Richard Daly, President and CEO of Visible Genetics Inc.

This test is intended to be used by health care providers as a tool for the management of HIV disease and in combination with all clinical and laboratory findings as well as the prescribed medication.

For additional information on the product, visit www.visgen.com.


Back to the December 2001/January 2002 issue of Positive Living.


This article has been reprinted at The Body with the permission of AIDS Project Los Angeles (APLA).




This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art32844.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.